Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment

Author:

Ode Yudai1ORCID,Pradipta Ambara R.1ORCID,Ishiwata Akihiro2ORCID,Nambu Akihiro3,Ohnuki Kazunobu4,Mizuma Hiroshi56,Haba Hiromitsu3,Tanaka Katsunori12ORCID

Affiliation:

1. Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, Tokyo 152-8552, Japan

2. Biofunctional Synthetic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

3. Nuclear Chemistry Group, RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

4. Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

5. Department of Functional Brain Imaging, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan

6. Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan

Abstract

Oligomeric 2,6-diisopropylphenyl azides, equipped with chelators to form stable complexes with metallic radionuclides, were developed as a new radionuclide therapy method that takes advantage of endogenous acrolein overproduced by cancer cells.

Funder

Japan Society for the Promotion of Science

Suntory Foundation for Life Sciences

Naito Foundation

Publisher

Royal Society of Chemistry (RSC)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3